WallStreetZenWallStreetZen

NASDAQ: CDAK
Codiak Biosciences Inc Stock

$0.81+0.06 (+8%)
Updated Feb 3, 2023
CDAK Price
$0.81
Fair Value Price
$2.86
Market Cap
$29.68M
52 Week Low
$0.30
52 Week High
$7.15
P/E
-1.26x
P/B
0.76x
P/S
0.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.07M
Earnings
-$17.42M
Gross Margin
100%
Operating Margin
-43.46%
Profit Margin
-51.1%
Debt to Equity
2.45
Operating Cash Flow
-$67M
Beta
1.53
Next Earnings
Mar 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CDAK Overview

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. The company has developed a platform, engEx Platform, to design, engineer, and manufacture exosome therapeutics. Its lead product candidates are exoSTING and exoIL-12 for the treatment of various solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, MA.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDAK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CDAK ($0.81) is undervalued by 71.85% relative to our estimate of its Fair Value price of $2.86 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CDAK ($0.81) is significantly undervalued by 71.85% relative to our estimate of its Fair Value price of $2.86 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CDAK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDAK due diligence checks available for Premium users.

Be the first to know about important CDAK news, forecast changes, insider trades & much more!

CDAK News

Valuation

CDAK fair value

Fair Value of CDAK stock based on Discounted Cash Flow (DCF)
Price
$0.81
Fair Value
$2.86
Undervalued by
71.72%
CDAK ($0.81) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDAK ($0.81) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDAK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CDAK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.26x
Industry
10.7x
Market
15.09x

CDAK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
5.11x
CDAK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CDAK's financial health

Profit margin

Revenue
$522.0k
Net Income
-$19.3M
Profit Margin
-3,693.1%
CDAK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDAK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$134.4M
Liabilities
$95.5M
Debt to equity
2.45
CDAK's short-term assets ($61.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDAK's long-term liabilities ($81.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDAK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.1M
Investing
-$9.0k
Financing
$20.1M
CDAK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CDAK vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CDAK$29.68M+7.47%-1.26x0.76x
SABS$29.69M-6.38%-0.96x0.97x
CYCN$29.71M-7.07%-0.63x1.80x
COEP$29.66M+0.67%-0.43x14.39x
BIOR$29.86M-3.92%-0.27x-0.31x

Codiak Biosciences Stock FAQ

What is Codiak Biosciences's quote symbol?

NASDAQ: CDAK) Codiak Biosciences trades on the NASDAQ under the ticker symbol CDAK. Codiak Biosciences stock quotes can also be displayed as NASDAQ: CDAK.

If you're new to stock investing, here's how to buy Codiak Biosciences stock.

What is the 52 week high and low for Codiak Biosciences (NASDAQ: CDAK)?

(NASDAQ: CDAK) Codiak Biosciences's 52-week high was $7.15, and its 52-week low was $0.30. It is currently -88.73% from its 52-week high and 168.67% from its 52-week low.

How much is Codiak Biosciences stock worth today?

(NASDAQ: CDAK) Codiak Biosciences currently has 36,829,626 outstanding shares. With Codiak Biosciences stock trading at $0.81 per share, the total value of Codiak Biosciences stock (market capitalization) is $29.68M.

Codiak Biosciences stock was originally listed at a price of $12.12 in Oct 14, 2020. If you had invested in Codiak Biosciences stock at $12.12, your return over the last 2 years would have been -93.35%, for an annualized return of -74.21% (not including any dividends or dividend reinvestments).

How much is Codiak Biosciences's stock price per share?

(NASDAQ: CDAK) Codiak Biosciences stock price per share is $0.81 today (as of Feb 3, 2023).

What is Codiak Biosciences's Market Cap?

(NASDAQ: CDAK) Codiak Biosciences's market cap is $29.68M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Codiak Biosciences's market cap is calculated by multiplying CDAK's current stock price of $0.81 by CDAK's total outstanding shares of 36,829,626.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.